|
Asia-Pacific Economic Cooperation (APEC) Cervical Cancer Initiative
|
Meeting/ Workshop
|
OS
|
NCI
|
On August 24-25, 2017, the US National Cancer Institute’s Center for Global Health (NCI/CGH), working in collaboration with the US Departments of State and Health and Human Services, led a Policy Dialogue and Workshop on Human Papillomavirus (HPV) and Cervical Cancer Control during the APEC meetings in Ho Chi Minh City, Vietnam. The primary goal this dialogue was to jointly promote strategies for implementation of the APEC Roadmap to Promote Sustainable Economic Advancement for Women through Cervical Cancer Prevention and Control (2016-2021), a guiding document approved by the APEC Health Working Group in early 2017 with a key goal of enhancing knowledge exchange opportunities. Specifically, this practical workshop focused on current evidence of cost-effectiveness and the investment benefits of HPV vaccination programs as well as how to collect and use data from pilot and large-scale programs to inform future decision-making.
|
|
Assisted Outpatient Treatment
|
Research Initiative
|
HRSA, SAMHSA
|
NIMH
|
This collaboration supports the development and implementation of a rigorous and objective cross-site impact evaluation of an Assisted Outpatient Treatment (AOT) Grant Program for Individuals with Serious Mental Illness. The Department of Health and Human Services, Assistant Secretary for Planning and Evaluation (ASPE) has primary responsibility for the solicitation, management, and implementation of the evaluation contract in consultation with the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute of Mental Health (NIMH). The Center for Behavioral Health Statistics and Quality (CBHSQ), an entity within SAMHSA that serves as a focal point for data collection, analysis, and the dissemination of critical public health data, will provide consultation on the cross-site evaluation of the AOT grant program. ASPE, in consultation with the NIMH, brings expertise in evaluation design and implementation that benefits SAMHSA in its priority of having a rigorous multi-site evaluation. The initial Phase I Implementation Evaluation was completed in FY2017. Results of the Implementation Evaluation are being used to inform the design and data collection plan for the Phase II Outcome Evaluation, which is scheduled to begin in FY 2019.
|
|
Autoimmune Diseases Coordinating Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NIAID, CSR, FIC, NCATS, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIBIB, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NINDS, NINR
|
The purpose of the Autoimmune Diseases Coordinating Committee (ADCC) is to provide a forum for the coordination of research efforts in autoimmunity and autoimmune diseases among various stakeholders including the National Institutes of Health (NIH), other federal agencies such as the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC), and private organizations with an interest in autoimmune diseases. The ADCC meets twice yearly to discuss a broad range of basic, preclinical, and clinical endeavors.
|
|
Bacteriophage Interest Group (Monthly Meeting)
|
Meeting/ Workshop
|
BARDA, FDA
|
NIAID
|
The purpose of this monthly meeting is to allowthe National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority(BARDA) and the Food and Drug Administration (FDA) to hear seminars on bacteriophage therapy and discuss progress in this area.
|
|
Bacteriophage Therapy: Intraagency meeting
|
Meeting/ Workshop
|
BARDA, FDA
|
NIAID
|
The purpose of this meeting was to exchange information regarding phage therapy with other United States Government (USG) stakeholders.
|
|
Best Pharmaceuticals for Children Act (BPCA) Data Monitoring Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NCI, NHLBI
|
The Best Pharmaceuticals for Children Act (BPCA) Data Coordinating Center (DCC) is responsible for managing all aspects of BPCA clinical trials including developing trial design, collecting and analyzing trial data, monitoring data quality, conducting site monitoring, collecting and preparing safety reports, organizing and submitting documentation to the Food and Drug Administration (FDA), and managing the Data Monitoring Committee.
|
|
Biological Select Agents and Toxins Interagency Policy Committee (BSAT PPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Discusses appropriate oversight of Select Agents and Toxins.
|
|
Biological Select Agents and Toxins sub-Interagency Policy Committee (BSAT Sub-PPC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
OD/OSP, NIAID
|
Discusses the appropriate oversight of Select Agents and Toxins; Subcommittee of the Biological Select Agents and Toxins Policy Coordination Committee (BSAT PPC).
|
|
Biomarkers of Exposure and Effect in Agriculture (BEEA)
|
Research Initiative
|
CDC
|
NCI
|
National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) are collaborating to characterize exposure to permethrin and other pesticides by measuring urinary metabolites among participants in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study.
|
|
Biomedical Research Integrated Domain Group (BRIDG) Standard Development
|
Research Initiative
|
FDA
|
NCI
|
Developing a conceptual data model that harmonize Electronic medical record (EMR) data and protocol driven data
|